Stockreport

Immatics Announces Third Quarter 2025 Financial Results and Business Update [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion [Read more]